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Abstract
Background: Smokers have increased susceptibility and altered innate host defense responses to influenza virus infection.
Broccoli sprouts are a source of the Nrf2 activating agentsulforaphane, and short term ingestion of broccoli sprout
homogenates (BSH) has been shown to reduce nasal inflammatory responses to oxidant pollutants.
Objectives: Assess the effects of BSH on nasal cytokines, virus replication, and Nrf2-dependent enzyme expression in
smokers and nonsmokers.
Methods: We conducted a randomized, double-blind, placebo-controlled trial comparing the effects of BSH on serially
sampled nasal lavage fluid (NLF) cytokines, viral sequence quantity, and Nrf2-dependent enzyme expression in NLF cells and
biopsied epithelium. Healthy young adult smokers and nonsmokers ingested BSH or placebo (alfalfa sprout homogenate)
for 4 days, designated Days -1, 0, 1, 2. On Day 0 they received standard vaccine dose of live attenuated influenza virus (LAIV)
intranasally. Nasal lavage fluids and nasal biopsies were collected serially to assess response to LAIV.
Results: In area under curve analyses, post-LAIV IL-6 responses (P = 0.03) and influenza sequences (P = 0.01) were
significantly reduced in NLF from BSH-treated smokers, whileNAD(P)H: quinoneoxidoreductasein NLF cells was significantly
increased. In nonsmokers, a similar trend for reduction in virus quantity with BSH did not reach statistical significance.
Conclusions: In smokers, short term ingestion of broccoli sprout homogenates appears to significantly reduce some virus-
induced markers of inflammation, as well as reducing virus quantity. Nutritional antioxidant interventions have promise as a
safe, low-cost strategy for reducing influenza risk among smokers and other at risk populations.
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Introduction
Influenza virus infection is a serious, large-scale global public
health problem. Current vaccines and antiviral drugs are only
partially effective against influenza, and may be ineffective in the
setting of epidemics due to antigenic shift or emergence of drug-
resistant strains [1,2]. Thus, novel strategies for controlling
influenza are needed, especially for susceptible subpopulations
such as those with chronic disease, or with chronic exposure to
airborne pollutants. Tobacco smoke has been repeatedly shown to
be a significant risk factor for severe influenza infection, whether
from active smoking [3–8] or from second-hand exposures [9].
Using transient low-level nasal infection with standard dose of
live attenuated influenza virus (LAIV) vaccine as a model, we have
previously shown that healthy young adult smokers have blunted
host defense responses to LAIV and enhanced viral replication,
compared to healthy nonsmokers [10]. We have also shown that
epithelial antiviral responses to influenza in vivo and in experi-
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Data Availability: All relevant data are within the paper and its Supporting Information files.
mental cell culture models are blunted in smokers, and that the
abnormalities can be corrected in vitrowith antioxidants including
sulforaphane(SFN) [11–13]. SFN, which has shown promise as a
potent antioxidant and chemopreventive agent due to its upregula-
tion ofNrf2-dependent, cytoprotective Phase II antioxidant enzy-
mesincluding heme oxygenase-1 (HMOX1) and NAD(P)H: quino-
neoxidoreductase (NQO1), is present in high concentrations in
broccoli sprouts [14,15]. Prior investigation in human volunteers
has demonstrated a measurable,dose-dependent, short-term effect
of broccoli-sprout homogenates on expression of Nrf2-dependent
enzymes in the upper airway [16]and in the skin [17]. Additionally,
broccoli sprouts were shown to reduce nasal allergic inflammation
after diesel particle exposure [18].
We hypothesized that short term ingestion of broccoli sprouts
would have a beneficial effect on nasal responses to influenza virus in
smokers, by preventing the enhanced virus quantity and blunted IL-
6 responses we observed in our previous study. Using LAIV as a
model infection as previously reported [10,19], we carried out an
interventional study in otherwise-healthy smokers and in nonsmok-
ing, healthy volunteers. Our results suggest that antioxidant-focused,
‘‘nutraceutical’’ approaches may be a promising strategy to pursue as
a low-costadjunct to existingapproaches for reducing the impact of
influenza on individuals exposed to airborne oxidant pollutants.
Materials And Methods
CONSORT checklist and IRB protocol
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design and subjects
To confirm that a broccoli sprout homogenate (BSH) prepara-
tion would upregulate antioxidant enzymes in nasal cells similarly
to the previously published study of Riedl et al. [16], we initially
conducted a pilot study in 10 healthy young adult volunteers. We
then carried out a randomized, double-blind, placebo-controlled
study measuring the effect of short-term ingestion of BSH,com-
pared to alfalfa sprout homogenate (ASH) controls, on nasal
mucosal host defense response to a standard nasal vaccine dose of
LAIV. Randomization was 1:1 and the randomization method
was by the permuted blocks method.
Subjects underwent screening for smoking history, informed
consent, and randomization. A baseline superficial scrape biopsy
of the epithelium was performed on the inferior surface of the
middle nasal turbinate and epithelial RNA was isolated. Three to
four weeks later, one BSH or alfalfa sprout control (ASH) shake
was ingested daily for 4 consecutive days, designated days 21, 0, 1,
and 2 (see belowfor preparation method). Shakes were ingested by
subjects under direct observation by study staff. On day 0, a
standard vaccine dose of LAIV (MedImmune, Inc.) was admin-
istered into each nostril as a nasal spray according to the
manufacturer’s recommendations. Nasal lavage was done on days
21, 0, 1, 2, 3, and 7. Anothersuperficial nasal biopsy on the
inferior surface of the middle turbinate was done on day 2 and
processed for qRT-PCR endpoints in similar fashion. Nasal lavage
fluid (NLF) and nasal biopsy material were used to measure host
defense factors and virus quantity, as described below.
Subjects were 18–40 years old, healthy, and had a history of
smoking defined as.0.5 pack/day. Subjects were instructed to
avoid cruciferous vegetables (which contain SFN) and anti-
inflammatory medications, including corticosteroids and non-
steroidal anti-inflammatory drugs, during the study period. A
history of either receiving influenza vaccine or having a documented
influenza infection in the previous year was a criterion for exclusion.
Additionally, a cohort of healthy nonsmokers with otherwise
identical inclusion and exclusion criteria were studied.
Both the pilot and the main study were approved by the UNC
Biomedical Institutional Review Board. The main study was
registered with ClinicalTrials.gov (Identifier: NCT01269723). All
subjects gave written informed consent. The start date of the study
was 1/24/2011 and the end date was 4/8/2013.
Preparation of sprout homogenates
BSH shakes were prepared similarly to a previously published
method [16]. One daily ‘‘dose’’ was 200 grams of BSH,containing
approximately 111 grams fresh sprouts (about one 4-ounce
package of Broccosprouts (Brassica Protection Products LLC)).
The homogenates wereprepared by our clinical/translational
research center’sNutrition Research and Metabolism Core, and
were homogenized with water using a ratio of 1:1.2 in a clean
blender. The same weight of alfalfa sprouts, which contain
minimal SFN, was prepared in an identical manner for the
placebo (ASH) treatment. Both BSH and ASH were prepared
from single lots of sprouts to insure uniform SFN dosing for the
study, and stored at 220uC in aliquots, and thawed for ingestion
the day prior to use. BSH and ASH shakes were labelled with
subject number only, to maintain blinding of subjects and research
staff administering the shakes.
Nasal lavage and biopsy
Nasal lavagewas performed according to a method we have
previously described [10] by repetitive spraying of sterile normal
saline irrigation solution (4 ml total) into the nostril, followed by
voluntary expelling of fluid by the subject into a specimen
collection cup. Both nostrils werelavaged in this way and the
resulting nasal lavage fluid (NLF) from both sides was combined.
NLF was centrifuged at 500g67 minutes to remove cells, and the
cell-free supernatant stored in aliquots at 280uC until used in
mediator assays. Total RNA was isolated from the cell pellets and
analyzed for the expression of antioxidant, inflammatory, and
immune genes as described below.
To biopsy nasal epithelium, cells were gently scraped from the
inferior surface of the middle turbinate on each side of the nose,
using a sterile plastic curette (Rhino-Probe, Arlington Scientific,
Arlington, TX). After determination of cell differential (by
morphology on Wright stain) and viability, specimens having .
85% viable epithelial cells were used for immediate processing for
qRT-PCR.
Urine cotinine
Urine cotinine was measured by ELISA (Bio-Quant, Inc., San
Diego, CA) and expressed as a ratio to creatinine, measured by a
colorimetric assay (Oxford Biomedical Research, Rochester Hills,
MI).
Cytokine assays
Concentration of IL-6, IP-10, and IL-8 in the cell-free nasal
lavage fluid was determined by enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer instructions (BD
Biosciences, San Jose, CA).
Influenza sequence quantitation and HMOX1 and NQO1
expression in NLF cells and nasal biopsy tissue by
quantitative RT-PCR
RNA isolation from NLF cells and nasal biopsy tissue stored in
Trizol, first-strand cDNA synthesis, and qRT-PCR were per-
Broccoli Sprouts and Response to Influenza
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formed as previously described [20]. For RT-PCR analysis,
primers for 18S, b-actin, (endogenous loading control) and
HMOX1, and NQO1 were commercially available (Applied
Biosystems, Grand Island, NY). Primers were designed
for Influenza A and Influenza B Matrix 2 genes as follows:
Influenza A Forward 59-GGGTGCAGATGCAACGAT-39, Re-
verse 59-AATATCAAGTGCAAGATCCCAATG-39, Probe 59-
I56-FAM/TGACCCTCTTGTTGTTGCCGC-39; Influenza B
Forward 59-GCAAGTAAAACTAGGAACGCTCTGT-39, Re-
verse 59-CTGAAGATCTTGCTGCTCTGCTAT-39, Probe 59-
I56-FAM/CGAGAAACAAGCATCACATTC-39 (Integrated
DNA technologies, Coralville, IA). qRT-PCR was performed
using and Applied Biosystems 7500 Real Time PCR system. Gene
expression was determined by the DDCt method using 18S
expression as an endogenous control for NLF cell samples and b-
actin as an endogenous control for nasal biopsy tissue samples.
Statistical analysis
The target sample size for the study was derived by estimating
the number of subjects needed to detect a significant effect of BSH
on NLF IL-6 response to LAIV, using area under curve data from
our previous study in smokers[10]. Based on this, the minimum
sample size required to detect a treatment effect of 150% of
placebo was estimated to be 17 subjects per treatment group.
The study’s primary endpoint was IL-6 in NLF after LAIV
inoculation, expressed as area under curve (AUC) for ratio of IL-6
(Days 1–3) to baseline (Day 0), in smokers. AUC was compared
between BSH and ASH groups using two-sample Student’s t test
[21]. Raw data were log-transformed in order to achieve normality
required for t test. Secondary endpoints were analyzed in similar
fashion and included influenza B RNA sequence quantity in NLF
cells; HO-1 and NQO1 mRNA in NLF cells; tolerance of BSH;
NLF cytokines other than IL-6 (IL-8, IP-10, IFN ); and nasal
biopsy influenza B RNA sequence quantity and antioxidant
enzyme mRNA. P,0.05 was considered statistically significant
throughout.
The study was also carried out in a healthy nonsmoking young
adult cohort for descriptive purposes. Data for nonsmokers were
analyzed similarly as for smokers, but nonsmokers were studied
with a different vaccine composition and were therefore not
formally compared to smokers in the data analysis. All endpoints




To confirm that our broccoli sprout homogenate (BSH)
preparation would upregulate antioxidant enzymes in nasal cells
similarly to the previously published study of Riedl et al. [16], we
initially conducted a pilot study in which 10 healthy young adult
volunteers underwent nasal lavage then ingested 1 BSH ‘‘shake’’
(see preparation method below) per day for 3 consecutive days.
Expression of HMOX1 in NLF cells was measured by qRT-PCR.
There was significantly increased median HMOX1 expression by
the third day (median 3.5 fold increase over baseline; interquartiles
2.5, 9.0) (P = .02). The magnitude of increase in expression
appeared to be related to baseline levels, such that subjects with
lower baselines had greater increases (Spearman R = -0.73,
P = 0.03). The majority of subjects reported mild gastrointestinal
symptoms including abdominal fullness, bloating or flatulence. No
severe symptoms were reported by any subject.
Subject characteristics
Study flow diagrams for the phases of recruitment, allocation,
and data analysis for the smokers and nonsmokers cohorts are
shown in Fig. 1. Smokers were more difficult to recruit and retain
in the protocol than were nonsmokers. Among smokers who
received the ASH or BSH intervention, 16/21 (76%)completed
sufficient attendance and samples for final area under curve data
analysis. By comparison, in nonsmokers35/37 (95%)of subjects
who received ASH or BSH intervention had sufficient data for
final analysis.
For the main randomized study, the demographic characteris-
tics of subjects for final data analysis are shown in Table 1. Within
each of the two separate study cohorts (smokers and nonsmokers),
there was symmetric distribution for age, gender, race and BMI
between treatment groups. Urine cotinine/creatinine ratios among
the smokers at the screen visit were not statistically different
between the ASH and BSH groups (P = 0.69), and were at levels
consistent with a history of active smoking [10](Table 1).
Smokers were studied during the 2010-11 and 2011-12 vaccine
‘‘seasons’’ and thus received LAIV containing the influenza strains
A/California/7/09 (H1N1)-like virus (pandemic (H1N1) 2009
influenza virus), A/Perth/16/2009 (H3N2)-like virus, and B/
Brisbane/60/2008-like virus. One additional smoker completed
the protocol in 2012-13, and thus received a vaccine with different
H3N2 (A/Victoria/361/2011-like) and B (B/Wisconsin/1/2010-
like) strains.Completion of the study by smokers fell short of the
study target goal, due to a combination of relatively low smoking
rates among local healthy young adults, poor compliance with the
BSH supplementation protocol, and a high dropout rate after
enrollment. Of 27 smokers who consented to participate, 11 (41%)
did not complete the study for reasons including the development
of illness before Day 0 or failure to return for all study visits. One
subject did not tolerate the taste of the broccoli shakes and
withdrew. Thus, 16 smokers completed the study.
Nonsmokers were studied in the 2012-13 vaccine season and
thus received LAIV containing the following influenza strains: A/
California/7/2009-like (pH1N1), A/Victoria/361/2011-like
(H3N2), and B/Wisconsin/1/2010-like. Of 42 nonsmokers who
consented to participate, 7 (17%) withdrew or were disqualified.
None reported intolerable taste or side effects from the shakes.
Thus, 35 nonsmokers completed the study.
Effect of BSH on cytokines in NLF
We analyzed the effect of BSH vs. ASH on nasal cytokines prior
to LAIV (Day 21 vs. Day 0), and after LAIV (area under curve for
Days 1–3 normalized to Day 0). Table 2 shows summarized NLF
cytokine data for smokers. The BSH group did not show a
statistically significant effect on pre-LAIV (Day 21 vs. day 0) levels
of any the cytokines assayed, compared to ASH. After LAIV, in
both treatment groups, IL-6 and IP-10 tended to increase over
Days 1–3, then declined to baseline levels by Day 7; and there was
little change in IL-8. These trends in response to LAIV were
consistent with our prior study in smokers [10]. Levels of IFN
were near the low end of the quantifiable range throughout the
study period (data not shown). BSH had no statistically significant
effect on the IL-8, IP-10, or IFN responses to LAIV. However, in
smokers, BSH was associated with significantly reduced IL-6
response to LAIV (logAUC 2.1360.79), compared to placebo
(logAUC3.2760.99) (P = 0.03) (Fig. 2). Fig. 2A suggests that this
reduction was mainly due to lack of an IL-6 response on study
days 1–2.
Table 2 also shows summarized NLF cytokine data for
nonsmokers. At baseline (prior to LAIV), BSH was associated
with a statistically significant but small decrease in IL-8 in
Broccoli Sprouts and Response to Influenza
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nonsmokers. Otherwise, BSH did not have a statistically different
effect on baseline (pre-LAIV) levels of the factors assayed, between
Day (21) and Day 0, compared to ASH controls. In both
treatment groups, consistent with our prior study[10], IL-6 and IP-
10 both increased over Days 1–3 following LAIV inoculation, then
declined to baseline levels by Day 7, and there was little change in
IL-8. IFN was again low for most subjects at most time points
(data not shown). The BSH effect on IL-6 noted in smokers did not
occur in nonsmokers, for whomthere were no statistically
significant effects of BSH compared to control on any of the
post-LAIV cytokines assayed, in the AUC analyses (Fig. 2). IL-6
levels and responses to LAIV were generally lower in smokers than
in nonsmokers, also consistent with our prior observations [10].
Effect of BSH on influenza quantity in NLF cells and nasal
biopsies
In NLF cells in smokers, no virus sequences were detectable in
any subject in either treatment group, at the Day (21) or Day 0
baselines, as expected; and other than on Day 1, the majority of
samples had undetectable levels of viral RNA. However, as shown
in Fig. 3, the BSH group had significantly reduced influenza B
sequence quantity (logAUC 23.6760.77), compared to the
placebo group (logAUC 21.9461.40)(P = 0.01). In nasal epithelial
biopsies obtained at study screening there were no viral sequences
detected in either treatment group, as expected. At Day 2, no viral
sequences were detected in any subject in the BSH group, whereas
influenza B sequences were detected in 2 of 10 controls, but the
effect was not statistically significant (data not shown).
In nonsmokers, a similar pattern of reduced virus sequences in
NLF cells was observed in the BSH group (Fig. 3).While the
median reduction in virus quantity appeared to be even greater
than that seen in the smokers (logAUC 21.8862.36 for BSH
compared to 20.4961.33 in controls), the variability was greater
and the effect was not statistically significant (P = 0.15).
Effects of BSH on expression of HMOX1 and NQO1 in NLF
cells and nasal biopsies
Data for expression of antioxidants HMOX1 and NQO1 in
NLF cells on each study day are shown in Table 3 for smokers.
BSH had no statistically significant effect on baseline (pre-LAIV)
expression of HMOX1 or NQO1, and the HMOX1 response to
LAIV as measured by AUC was not significantly altered by BSH.
Figure 1. Flow diagram for recruitment and randomization of subjects for the (A) smokers and (B) nonsmokers cohorts in this
study. URI = upper respiratory illness.
doi:10.1371/journal.pone.0098671.g001
Table 1. Demographic characteristics of subjects completing the randomized controlled study. Data are in mean 6 SE except
where indicated otherwise.
Cohort Treatment arm Age (yr) Gender1 BMI Race2 Urine cotinine3
Smoker ASH(N = 10) 28.161.3 3/10 27.662.0 4/5/1 194631
BSH(N = 6) 27.361.7 2/6 27.261.4 4/2/0 3136132
Nonsmoker ASH(N = 20) 26.961.3 14/20 24.960.8 15/5/0 N/A
BSH(N = 15) 26.061.3 7/15 25.560.9 10/4/1 N/A
1Female/total.
2White/African American/Asian.
3expressed as ng cotinine x 100/mg creatinine at Screen visit.
doi:10.1371/journal.pone.0098671.t001
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NQO1 response to LAIV in NLF cells, as measured by AUC for
Days 1–3 normalized to Day 0, was significantly increased in the
BSH group (54.4647.4) compared to ASH (23.2620.2) (P = 0.04).
Inspection of the raw data medians for time course of NQO1 in
NLF cells in smokers (Table 3) suggests that this was because the
Day 0 baseline was lower in the BSH group, but the Day (21) level
prior to BSH treatment also appeared to be lower in this group. A
similar pattern in the raw data was noted for nonsmokers (Table 3),
but there was no significant difference between treatment groups
in the AUC analysis.
To assess the effect of BSH on epithelial expression of HMOX1
and NQO1 in the setting of LAIV infection, the ratio of Day 2 to
screen day mRNA expression was measured in the nasal biopsies
and compared between the treatment groups. In smokers, the
median HMOX1 expression ratio was higher in the BSH group
(Table 4) but this was not statistically significant (P = 0.36). There
was no statistically significant BSH effect con NQO1 compared to
control in smokers. There was no statistically significant effect of
BSH on epithelial expression of HMOX1 or NQO1 for
nonsmokers. Epithelial expression of NQO1 tended to be higher
in the smokers than in the nonsmokers (Table 4), both at baseline
and after LAIV.
Given the apparent relationship between baseline HMOX1
expression in NLF cells and subsequent response to BSH in the
pilot study, for descriptive purposes we assessed the correlation
between baseline expression and subsequent response to BSH, for
HMOX1 and NQO1 (Fig. 4). For both NLF cells (Fig. 4 A, B) and
nasal biopsy cells (Fig. 4 C,D), lower initial (screen day) expression
of the antioxidant enzymeswere associated with greater ‘‘respons-
es’’ to BSH.
Discussion
Smokers are at increased risk for influenza infection [3–8,22]
and we have previously shown that their nasal mucosal IL-6 and
IP-10 responses to LAIV are blunted [10]. In a randomized study
of young adult smokers, we have shown here that short term
ingestion of a nutritional supplement intended to upregulate
antioxidant levelssignificantly reduces IL-6 response and virus
quantity, while possibly enhancing NQO1 expression in epithe-
lium. Based on our prior in vitro studies in nasal epithelial cells
[11,13], we hypothesized that BSH reduced viral replication by
reducing oxidative stress in nasal cells, resulting in secondary
reduction in downstream host defense responses including IL-6
production. Some of these results, particularly suppression of virus
quantity, appeared to show a similar tendency in a cohort of
healthy nonsmokers studied separately, though the results were not
statistically significant.
Figure 2. IL-6 in nasal lavage fluids (NLF) and IL-6 area under curve (AUC) for Days 1–3 normalized to Day 0, for smoker and
nonsmoker study groups. Data for raw IL-6 in NLF (A, B) are shown as medians on each study day, for each treatment group. Data for AUC (C,
D)are for individual subjects; bar indicates median for treatment group. During the ‘‘Treatment period’’ subjects received broccoli sprout
homogenates (BSH) or alfalfa homogenates as control (ASH) once daily. Live attenuated influenza virus (LAIV) was inoculated nasally on Day 0, after
nasal lavage. * P,.05 for BSH vs. ASH.
doi:10.1371/journal.pone.0098671.g002
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Airway tissues from smokers are under chronic oxidative stress
[23]and a relationship between cellular oxidative stress and
susceptibility to respiratory virus infection has been described
previously. Macchia et al. reported that inhibition of glutathione
(GSH) synthesis in epithelial cells leads to increased replication of
Sendai virus. [24] In our own studies comparing differentiated
nasal epithelial cells from smokers and nonsmokers, we have
reported both increased influenza replication and suppression of
antiviral pathways in cells from smokers. [11] We have also found
that treatment of human respiratory epithelium with Nrf2-
activating agents including SFN and EGCG, as well as
GSH,inhibits influenza replication in nasal epithelial cells; the
mechanisms in vitro appear to include both upregulation of
antiviral pathway elements and increased ratio of antiproteases
to proteases, which in turn inhibits the proteolytic activation of
influenzahemagglutinin, which is necessary for initial binding and
entry of the virus. [13,25] Animal models have also suggested that
manipulation of Nrf2 activation can affect viral replication. Cho et
al reported that Nrf22/2 mice had increased pulmonary inflam-
mation and severity of disease compared to wild type, and
pretreatment with SFN reduced illness in Nrf2+/+ mice [26].
Finally, in a murine model of tobacco smoke-induced oxidative
stress, the ‘‘mucoregulatory’’ compound S-carboxymethylcysteine
reduced both influenza replication and pulmonary inflammation,
while activating Nrf2. [27]Thus, Nrf2-enhancing supplementation
strategies may reduce susceptibility to respiratory virus infections,
especially in populations under chronic oxidative stress, such as
smokers.
Broccoli sprouts have been previously investigated as a
concentrated source of precursors of the potent Nrf2 inducingi-
sothiocyanate compound sulforaphane (SFN) [28]. In humans,
SFN has been studied as a chemopreventive agent [29], as a phase
II enzyme inducer to protect against the pro-inflammatory effects
of diesel exhaust particles in airway epithelium [30], and is
currently being examined in the context of COPD
(NCT01335971), based on the findings that upregulatingNrf2
may inhibit progression of the disease [31,32]. Riedl et al. [16]
reported that ingestion of broccoli sprout homogenates resulted in
dose-dependent increased expression of Phase II enzymes over
baseline, including HMOX1 and NQO1, in NLF cells from
human volunteers, an effect not seen with alfalfa sprouts; the BSH
and control preparations and ‘‘doses’’ we used in the present study
were modeled after this. It was also recently reported by Heber
et al. [18] that broccoli sprout extracts at a similar dose, given for 4
days, had a suppressive effect on diesel particle-induced allergic
inflammation in volunteers with allergic rhinitis. Hence, SFN-
containing broccoli sprout extracts have been examined in relation
tochronic inflammatory lung diseases and additional clinical trials
are underway assessing the potential of this ‘‘nutraceutical’’ in this
context.
In addition to our data shown here, several randomized,
placebo-controlled studies of the effect of nutritional or antioxidant
Figure 3. Influenza B RNA sequence quantity in nasal lavage fluid cells for (A) smokers and (B) nonsmokers. Data are shown as
medians on each study day, for each treatment group. During the ‘‘Treatment period’’ subjects received broccoli sprout homogenates (BSH) or
placebo control (alfalfa sprout shakes) once daily. Live attenuated influenza virus (LAIV) was inoculated nasally on Day 0, after nasal lavage. (C) and (D)
are area under curve data (Day 1–3, normalized to Day 0 baseline) for smokers and nonsmokers respectively. Bar indicates median for treatment
group. * P,.05 for BSH vs. ASH (AUC).
doi:10.1371/journal.pone.0098671.g003
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supplements on influenza infection or vaccine effectiveness have
been reported. For example, Vitamin D3 supplementation was
associated with a reduction in antigen-positive influenza A
infection from 18% to 10% in school children [33], and may
have decreased the incidence of asthma exacerbation. In a double-
blind randomized trial, cranberry juice, which has high concen-
tration of polyphenols and antioxidant activity, was consumed
daily for 10 weeks and resulted in reduced cold and flu symptoms
as well as markedly enhanced proliferation of peripheral blood -
T cells after PHA stimulation ex vivo [34]. In another double-blind
placebo-controlled study, fucoidan, a sulfated polysaccharide
extracted from seaweed, was shown to enhance antibody
Table 4. Effect of BSH and control treatments on HMOX1 and NQO1 mRNA expression in biopsied nasal epithelium, expressed as
ratio of Day 2 to screen day, in Smokers.
Cohort Endpoint Arm Screen Day 2 Treatment effect (Day 2/Screen)
Smokers HMOX1 ASH 1.18 (0.84, 3.41) 0.90 (0.60, 1.53) 0.92(0.21, 2.21)
BSH 1.09 (0.76, 2.86) 2.09 (0.91, 2.93) 1.49(0.80, 2.24)
NQO1 ASH 0.35 (0.23, 0.47) 0.36 (0.21, 0.46) 0.99(0.62, 1.42)
BSH 0.42 (0.26, 0.66) 0.53 (0.28, 0.72) 0.93(0.76, 1.88)
Nonsmokers HMOX1 ASH 0.93 (0.56, 1.38) 0.88 (0.53, 1.73) 1.01(0.56. 1.84)
BSH 0.76 (0.39, 1.90) 1.23 (0.59, 1.79) 1.14(0.65, 2.34)
NQO1 ASH 0.14 (0.10, 0.22) 0.15 (0.11, 0.26) 1.13(0.85, 1.89)
BSH 0.13 (0.09, 0.20) 0.17 (0.13, 0.27) 1.37(0.93, 1.63)
Data are shown as median (interquartiles). Treatment arms: ASH = control (alfalfa sprout homogenate), BSH = broccoli sprout homogenate.
doi:10.1371/journal.pone.0098671.t004
Figure 4. Relationship of baseline (screen day) mRNA quantity of antioxidant enzymes cells to magnitude of change in mRNA
quantity after LAIV, in subjects who received BSH. Data are shown for (A) HMOX1 and (B) NQO1 in NLF cells (AUC for Days 1–3 normalized to
baseline), and for (C) HMOX1 and (D) NQO1 in nasal epithelial biopsy cells (ratio of Day 2 biopsy to screen day). Data for smokers are shown as red
dots and nonsmokers as black dots. R and P values are for Spearman correlation coefficient, for smokers and nonsmokers who received BSH,
considered together.
doi:10.1371/journal.pone.0098671.g004
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production to trivalent influenza vaccine in elderly Japanese
volunteers, possibly associated with enhanced NK cell activity[35].
An herbal mixture of Echinacea, propolis, and Vitamin C taken
for 12 weeks reduced upper respiratory infections in children[36].
Green tea catechins and threonine taken in capsule form reduced
the incidence of clinically-defined influenza illnesses in Japanese
health care workers from 13% to 4% [37]. Our study thus adds to
a small but growing body of randomized controlled studies
supporting the concept that nutritional factors can alter specific
host defense responses and could thus potentially play an
important role in reducing the severity of influenza.
We sought evidence for upregulation of the Nrf2-dependent
antioxidant enzymes HMOX1 and NQO1 in nasal cells in our
BSH treated volunteers. While there was a statistically significant
elevation in AUC for NQO1 in NLF cells of smokers treated with
BSH, we did not see a significant effect of BSH on HMOX1. It is
possible our subject population was heterogeneous for baseline
oxidant stress. Though our study was not designed to test dose
response or pre-existing ‘‘deficiency’’ of antioxidants, the impact of
BSH on expression of HMOX1 and NQO1 after infection may
have been linked to baseline levels, i.e. the lower the starting levels
of expression, the greater the impact. Interestingly, this pattern
appeared to be present in both smokers and nonsmokers (Fig. 4). It
seems plausible that nutritional interventions aimed at boosting
antioxidants may be most effective in individuals who are relatively
antioxidant-deficient at baseline, a condition likely to be more
prevalent in smokers. [23]
Our study had several limitations. The infection induced by the
LAIV vaccine is inherently limited as a model for natural
infection, since the vaccine is specifically designed to have only
limited replication in the upper airway, a feature which makes the
model safe but places constraints on how generalizable or clinically
relevant the study conclusions are for community-acquired
influenza infections. Since our purpose was to study LAIV as a
model infection rather than as a vaccine, we focused on shorter-
term innate immunity endpoints, and did not assess longer term
effects of BSH on immune responses to LAIV. To minimize
altered responses to LAIV due to prior influenza exposures, we
excluded subjects with a history of either vaccination or influenza
in the past 12 months, but serologic screening could have
confirmed an immunologically naı̈ve subject population. We had
relative difficulty with recruitment and retention of subjects in the
smokers cohort, resulting in a smaller N than originally targeted.
Ingestion of the kind of BSH used in the study described here
may not be feasible to enhance mucosal host defense in the general
public; however, based on our in vitro studies [11,13] activation of
Nrf2-dependent pathways are mechanistically linked to the SFN-
induced protection against respiratory virus infection, suggesting
that other Nrf2-activating agents may have similar effects. For
example, the benefit of synthetic or naturally occurring triterpe-
noids, which have significantly greater potency in activating Nrf2
[38], may need to be explored in the context of viral infection.
Despite some of thelimitations described above, we believe our
study to be the first randomized, placebo controlled trial
suggesting a measurable effect of a short-term nutritional
intervention on specific mucosal host defense responses to
influenza, and perhaps virus replication, in humans. Our study
focused on specific host defense factors using a relatively artificial
model, and its clinical significance is unclear. However, our results
are encouraging as proof of concept for further study of the
strategy of developing nutritional antioxidants as an additional,
low-costand low-risk measure for reducing the impact of influenza.
This may be especially true for subgroups with underlying risk
factors related to chronic smoke exposure, pre-existing poor
nutrition, or underlying disease. While our study was not designed
to directly compare the effects of broccoli sprouts in smokers vs.
nonsmokers, we speculate that nonsmokers with relative antiox-
idant deficiency could also benefit from this approach.
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